TY  - JOUR

T1  - Cost-effectiveness (CE) of lapatinib plus capecitabine (L plus C) in women with HER2+metastatic breast cancer (MBC) who received prior therapy with trastuzumab (TZ) based on updated survival data from EGF100151

JO  - JOURNAL OF CLINICAL ONCOLOGY

PY  - 2008/05/20

AU  - DeLea T

AU  - Tappenden P

AU  - Sofrygin O

AU  - Karnon J

AU  - Amonkar M

AU  - Browning D

AU  - Rudge HJ

AU  - Walker MD

ED  - 

DO  - DOI: 10.1200/jco.2008.26.15_suppl.6559

VL  - 26

IS  - 15

Y2  - 2024/12/21

ER  -